A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06372865 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2014
At a glance
- Drugs PF 6372865 (Primary) ; Lorazepam
- Indications Pain
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 16 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Jul 2014, as per ClinicalTrials.gov record.
- 25 Feb 2014 Planned number of patients changed from 32 to 42, as per ClinicalTrials.gov record.